The laboratory mouse is widely considered as a valid and affordable model organism to study human disease. Attempts to improve the relevance of murine models for the investigation of human pathologies led to the development of various genetically engineered, xenograft and humanized mouse models. Nevertheless, most preclinical studies in mice suffer from insufficient predictive value when compared with cancer biology and therapy response of human patients. We propose an innovative strategy to improve the predictive power of preclinical cancer models. Combining (i) genomic, tissue engineering and regenerative medicine approaches for rational design of mouse models with (ii) rapid prototyping and computational benchmarking against human clinical data will enable fast and nonbiased validation of newly generated models.

实验室小鼠被广泛认为是研究人类疾病的有效且负担得起的模型生物。试图改善鼠模型与人类病理学研究的相关性的尝试导致了各种基因工程，异种移植和人源化小鼠模型的发展。然而，与人类患者的癌症生物学和治疗反应相比，大多数小鼠临床前研究的预测价值不足。我们提出了一种创新的策略，以提高临床前癌症模型的预测能力。将（i）合理设计小鼠模型的基因组，组织工程学和再生医学方法与（ii）针对人类临床数据的快速原型设计和计算基准相结合，将能够对新生成的模型进行快速且无偏见的验证。